AU2016228751B2 - Rp2 vectors for treating x-linked retinitis pigmentosa - Google Patents

Rp2 vectors for treating x-linked retinitis pigmentosa Download PDF

Info

Publication number
AU2016228751B2
AU2016228751B2 AU2016228751A AU2016228751A AU2016228751B2 AU 2016228751 B2 AU2016228751 B2 AU 2016228751B2 AU 2016228751 A AU2016228751 A AU 2016228751A AU 2016228751 A AU2016228751 A AU 2016228751A AU 2016228751 B2 AU2016228751 B2 AU 2016228751B2
Authority
AU
Australia
Prior art keywords
vector
mammal
retina
rpgr
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016228751A
Other languages
English (en)
Other versions
AU2016228751A1 (en
Inventor
Suja HIRIYANNA
Suddhasil MOOKHERJEE
Anand Swaroop
Zhijian Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Health and Human Services
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of AU2016228751A1 publication Critical patent/AU2016228751A1/en
Application granted granted Critical
Publication of AU2016228751B2 publication Critical patent/AU2016228751B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C07K14/4706—Guanosine triphosphatase activating protein, GAP
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C12N15/8645—Adeno-associated virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU2016228751A 2015-03-11 2016-03-11 Rp2 vectors for treating x-linked retinitis pigmentosa Active AU2016228751B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562131661P 2015-03-11 2015-03-11
US62/131,661 2015-03-11
PCT/US2016/022072 WO2016145345A1 (en) 2015-03-11 2016-03-11 Rp2 and rpgr vectors for treating x-linked retinitis pigmentosa

Publications (2)

Publication Number Publication Date
AU2016228751A1 AU2016228751A1 (en) 2017-09-21
AU2016228751B2 true AU2016228751B2 (en) 2022-01-13

Family

ID=56879752

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016228751A Active AU2016228751B2 (en) 2015-03-11 2016-03-11 Rp2 vectors for treating x-linked retinitis pigmentosa

Country Status (6)

Country Link
US (2) US10646588B2 (enExample)
EP (2) EP3719134B1 (enExample)
JP (2) JP6935049B2 (enExample)
AU (1) AU2016228751B2 (enExample)
CA (1) CA2979229A1 (enExample)
WO (1) WO2016145345A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2979229A1 (en) 2015-03-11 2016-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rp2 vectors for treating x-linked retinitis pigmentosa
SMT202400321T1 (it) * 2017-11-15 2024-11-15 Univ Michigan Regents Vettori virali comprendenti regioni codificanti rdh12 e metodi di trattamento di distrofie retiniche
TW202028225A (zh) * 2018-09-21 2020-08-01 英商夜星克有限公司 用於治療色素性視網膜炎之組合物及方法
CA3131023A1 (en) * 2019-02-22 2020-08-27 Michael R. Volkert Oxr1 gene therapy
KR20220049619A (ko) * 2019-08-30 2022-04-21 베이롤 칼리지 오브 메드신 유전자 발현 조절 시스템
WO2021178668A1 (en) * 2020-03-04 2021-09-10 University Of Massachusetts Compositions and methods for modulating rpgr expression
EP4511496A4 (en) * 2022-04-18 2026-06-24 Abeona Therapeutics Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF DOMINANT OPTIC ATROPHY AND X-RELATED RETINOSCHISISIS
CN117165596A (zh) * 2022-05-27 2023-12-05 武汉纽福斯生物科技有限公司 编码rpgr的核酸及其应用
WO2026119796A1 (en) * 2024-12-05 2026-06-11 Beacon Therapeutics Limited Gene therapy vector

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014011210A1 (en) * 2012-07-11 2014-01-16 The Trustees Of The University Of Pennsylvania Aav-mediated gene therapy for rpgr x-linked retinal degeneration

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010086A1 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Methods using cre-lox for production of recombinant adeno-associated viruses
EP2242840B1 (en) 2008-01-29 2019-07-24 Applied Genetic Technologies Corporation Recombinant adeno-associated virus production using bhk cells in suspension
US20100081707A1 (en) * 2008-02-21 2010-04-01 Ali Robin R Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea
CA2837322C (en) 2011-05-26 2023-03-21 University Of Washington Cell and gene based methods to improve cardiac function
AU2014216160B2 (en) * 2013-02-15 2017-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services AAV8 retinoschisin expression vector for treating X-linked retinoschisis
CN105209619B (zh) * 2013-03-11 2018-10-12 泰莱托恩基金会 miR-204和miR-211及其用途
EP3132051B1 (en) * 2014-04-15 2019-03-20 Applied Genetic Technologies Corporation Codon optimized nucleic acid encoding a retinitis pigmentosa gtpase regulator (rpgr)
LT3137497T (lt) * 2014-05-02 2021-07-26 Genzyme Corporation Aav vektoriai, skirti tinklainės ir cns genų terapijai
GB201412011D0 (en) * 2014-07-04 2014-08-20 Ucl Business Plc Treatments
SMT202000715T1 (it) * 2014-07-24 2021-01-05 Massachusetts Eye & Ear Infirmary Terapia genica rpgr per la retinite pigmentosa
CA2979120A1 (en) * 2015-03-03 2016-09-09 Fondazione Telethon Multiple aav vector system for expressing genes over 5 kilobases, comprising at least one degradation signal and uses thereof
CA2979229A1 (en) * 2015-03-11 2016-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rp2 vectors for treating x-linked retinitis pigmentosa

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014011210A1 (en) * 2012-07-11 2014-01-16 The Trustees Of The University Of Pennsylvania Aav-mediated gene therapy for rpgr x-linked retinal degeneration

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Late Breaking Abstracts: Presented at the American Society of Gene & Cell Therapy’s 16thAnnual Meeting, May 15–18, 2013, Salt Lake City, Utah", MOLECULAR THERAPY, ELSEVIER INC., US, vol. 21, no. 9, 6 September 2013 (2013-09-06), US , pages e1 - e46, XP055258076, ISSN: 1525-0016, DOI: 10.1038/mt.2013.140 *
LEWIN, A. et al., "AAV-mediated gene therapy in animal models of autosomal dominant and X-linked retinitis pigmentosa", Molecular Syndromology, (2011), vol. 2, no. 6, page 265 *
N/A: "Abstracts of 17th Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy (ASGCT), ", MOLECULAR THERAPY, ELSEVIER INC., US, vol. 22, no. Suppl.1., 1 June 2014 (2014-06-01), US , pages S1 - S306, XP055310541, ISSN: 1525-0016, DOI: 10.1038/mt.2014.64 *
SUDDHASIL MOOKHERJEE ET AL: "A Low Dose AAV Vector Administration Preserves Cone Function in an Rp2 Knockout Mouse Model for Retinitis Pigmentosa", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 55, no. 13, 1 January 2014 (2014-01-01), XP055310549 *
W. A. BELTRAN, A. V. CIDECIYAN, A. S. LEWIN, S. IWABE, H. KHANNA, A. SUMAROKA, V. A. CHIODO, D. S. FAJARDO, A. J. ROMAN, W.-T. DEN: "Gene therapy rescues photoreceptor blindness in dogs and paves the way for treating human X-linked retinitis pigmentosa", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 109, no. 6, 7 February 2012 (2012-02-07), pages 2132 - 2137, XP055155762, ISSN: 00278424, DOI: 10.1073/pnas.1118847109 *
ZHIJIAN WU ET AL: "Preclinical Development of AAV Vectors for the Treatment of X-linked Retinitis Pigmentosa Caused by RPGR Mutations ", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 55, no. 13, 1 January 2014 (2014-01-01), pages 3305, XP055310512 *

Also Published As

Publication number Publication date
AU2016228751A1 (en) 2017-09-21
JP2021019611A (ja) 2021-02-18
EP3268481B1 (en) 2020-05-27
US11617801B2 (en) 2023-04-04
CA2979229A1 (en) 2016-09-15
US20200289670A1 (en) 2020-09-17
EP3268481A4 (en) 2018-03-21
US10646588B2 (en) 2020-05-12
WO2016145345A1 (en) 2016-09-15
JP6935049B2 (ja) 2021-09-15
EP3719134B1 (en) 2023-08-23
EP3268481A1 (en) 2018-01-17
JP2018509154A (ja) 2018-04-05
US20180043035A1 (en) 2018-02-15
EP3719134A1 (en) 2020-10-07

Similar Documents

Publication Publication Date Title
US11617801B2 (en) RP2 and RPGR vectors for treating X-linked retinitis pigmentosa
US20250243509A1 (en) Methods for treating eye disease
Komáromy et al. Gene therapy rescues cone function in congenital achromatopsia
AU2013287281B2 (en) AAV-mediated gene therapy for RPGR x-linked retinal degeneration
JP6827320B2 (ja) ＬＣＡ−８及び進行性ＲＰを治療するための組換えＡＡＶ−Ｃｒｕｍｂｓホモログ組成物及び方法
JP7170656B2 (ja) Ｍｅｃｐ２ベースの治療
JP6449175B2 (ja) 眼の遺伝子関連疾患の治療のための方法及び組成物
JP7766393B2 (ja) 眼疾患のための遺伝子療法
US20240218394A1 (en) Gene therapy for ocular disorders
JP7671790B2 (ja) 眼疾患の遺伝子治療
JP2021510301A (ja) 網膜障害を治療するための組成物及び方法
KR20180072713A (ko) 클로라이드 채널의 표적된 발현 및 이의 사용 방법
CA3102095A1 (en) Compositions and methods for treatment of dominant retinitis pigmentosa
Fu et al. Clinical applications of retinal gene therapies
US12496328B2 (en) Compositions for the treatment of sarcopenia or disuse atrophy
Hassan et al. The dose-response relationship of subretinal gene therapy with rAAV2tYF-CB-h RS1 in a mouse model of X-linked retinoschisis
US10258672B2 (en) Compositions and methods of treating root avulsion injury
US20110301228A1 (en) Gene therapy vector for treatment of steroid glaucoma
US20230135501A1 (en) Gene therapy
US20240124893A1 (en) Methods of Treating Human X-Linked Retinoschisis Using Gene Therapy
ES2901613T3 (es) Lebecetina, una lectina de tipo C, como inhibidor de la neovascularización

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)